Velasof Tablet

To treat chronic hepatitis C (HCV) infection.

Most side effects of Velasof Tablet do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.
​Mood changes
Unusual weakness
Allergic reactions, including skin rash and itching
Shortness of breath
Swelling of the face
Slow heartbeat
Insomnia
Trouble in concentratingTiredness
Diarrhea
Nausea
Sleeping difficulty
Irritability
Loss of appetite
Muscle pain
Sudden cramps
Back pain
Headache

​Take the Velasof Tablet exactly as your healthcare provider tells you. Do not alter the dose strength unless your doctor tells you. Seek emergency medical help in case of overdose.

​The effect of Velasof 400 mg (recommended dosage) and 1200 mg (three times the recommended dosage) on the QTc interval was demonstrated in an active-controlled (moxifloxacin 400 mg) thorough QT trial. Sofosbuvir (Velasof) does not prolong QTc to any clinically relevant extent, at three times the recommended dose. The effect of Velpatasvir (Velasof) 500 mg (five times the recommended dosage) was demonstrated in an active-controlled (moxifloxacin 400 mg) thorough QT trial. Velpatasvir (Velasof) does not prolong the QTc interval to any clinically relevant extent at five times the recommended dose.

​If you miss a dose of Velasof Tablet, take it as soon as you remember. However, if it is already time for the next dose, please contact your healthcare provider. Do not double the dose to catch up.​

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

de Avelar, C. R., Nunes, B. V. C., da Silva Sassaki, B., Vasconcelos, M. D. S., de Oliveira, L. P. M., Lyra, A. C., Bueno, A. A. (2023). Efficacy of silymarin in patients with non‑alcoholic fatty liver disease—the SILIVER trial: a randomized controlled clinical trial protocol. Trials, 24(177). https://doi.org/10.1186/s13063-023-07210-6

Imam, S. S., Alshammari, S. O., Alshehri, S., Mahdi, W. A., & Al‑Agamy, M. H. (2024). Formulation of silymarin surface‑modified vesicles: in vitro characterization to cell viability assessment. Saudi Pharmaceutical Journal, 32(6), 102072. https://doi.org/10.1016/j.jsps.2024.102072

Navarro, V. J., Belle, S. H., D’Amato, M., Adfhal, N., Brunt, E. M., Fried, M. W., Harrison, S. (2019). Silymarin in non‑cirrhotics with non‑alcoholic steatohepatitis: a randomized, double‑blind, placebo‑controlled trial. PLoS One, 14(9), e0221683. https://doi.org/10.1371/journal.pone.0221683